Membrane-associated binding sites for estrogen may mediate rapid eects of estradiol-17b that contribute to proliferation of human breast cancers. After controlled homogenization and fractionation of MCF-7 breast cancer cells, the bulk of speci®c estradiol binding is found in nuclear fractions. However, a signi®cant portion of speci®c, high-anity estradiol-17b binding-sites are also enriched in plasma membranes. These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are free from major contamination by cytosol or nuclei. Electrophoresis of membrane fractions allowed detection of a primary 67-kDa protein and a secondary 46-kDa protein recognized by estradiol-17b and by a monoclonal antibody directed to the ligand-binding domain of the nuclear form of estrogen receptor. Estrogen-induced growth of MCF-7 breast cancer cells in vitro was blocked by treatment with the antibody to estrogen receptor and correlated closely with acute hormonal activation of mitogenactivated protein kinase and Akt kinase signaling. Estrogen-promoted growth of human breast cancer xenografts in nude mice was also signi®cantly reduced by treatment in vivo with the estrogen receptor antibody. Thus, membrane-associated forms of estrogen receptor may play a role in promoting intracellular signaling for hormone-mediated proliferation and survival of breast cancers and oer a new target for antitumor therapy. Oncogene (2001) 20, 5420 ± 5430.
Introduction
The growth of breast cells is normally regulated by hormones such as estrogen which bind estrogen receptors (ER). These receptors are present in more than two-thirds of breast cancers at diagnosis (Henderson et al., 1988) . According to prevailing theories of hormone action, estradiol-17b (E 2 b) diuses passively across plasma membranes and binds with nuclear receptors (Evans, 1988; Murdoch and Gorski, 1991) . The newly formed E 2 b-receptor complex may regulate gene expression by binding estrogen-responsive elements in target genes or by modifying transcription via interaction with other nuclear proteins (McKenna and O'Malley, 2000) . These nuclear events are believed to culminate in promotion of cell growth. However, in addition to this mechanism, many rapid eects of estrogen with an onset in seconds have been documented in breast (Aronica et al., 1994; Levin, 1999) and other tissues Ramirez and Zheng, 1996; Mendelsohn and Karas, 1999; Watson and Gametchu, 1999) . The time course of these events suggests that they do not require precedent gene activation. Rather, many rapid eects of estrogens may be due to activation of membrane-associated signaling pathways.
There is increasing evidence that membrane-associated forms of steroid hormone receptors exist and participate in activation of signaling pathways associated with gene regulation Ramirez and Zheng, 1996; Levin, 1999; Watson and Gametchu, 1999) . Estrogens are known to trigger rapid stimulation of guanylate and adenylate cyclases (Szego and Davis, 1967; Aronica and Katzenellenbogen, 1993; Aronica et al., 1994; Levin, 1999) , Ca 2+¯u x (Pietras and Szego, 1975) , nitric oxide synthase (Mendelsohn and Karas, 1999) and protein phosphorylation (Migliaccio et al., 1996) . In addition, E 2 b activates within seconds mitogen-activated protein kinase (MAPK) signaling cascades in responsive tissues (Migliaccio et al., 1996) . Although activation of these pathways is generally considered to be restricted to transmembrane receptors for peptide hormones and growth factors, the presence of high-anity receptors for E 2 b associated with the surface membrane of target cells was ®rst reported more than two decades ago (Pietras and Szego, 1977) . Proteins immunoreactive with antibodies to nuclear ER occur at the surface membrane of cells that exhibit rapid biologic responses to E 2 b (Pappas et al., 1995; Chambliss et al., 2000; Russell et al., 2000) . Chinese hamster ovary (CHO) cells transfected with expression constructs for ER have also been shown to express a portion of ER protein on their surface and to respond to estrogen with rapid membrane-initiated eects (Razandi et al., 1999) . These data have led to a growing recognition that the genomic model of estrogen action is incomplete and must be expanded to include membrane-associated receptors as a component of cell signaling (Pietras and Szego, 1977; Nemere and Farach-Carson, 1998; Levin, 1999; Watson and Gametchu, 1999) .
In the present study, we demonstrate that human breast cancer cells contain a membrane-associated binding site for estrogen that closely resembles nuclear ER. Activation of this membrane-associated receptor appears to promote rapid stimulation of MAPK and Akt kinase signaling and later cell proliferation. Biologic activity of the membrane-associated receptor can be diminished in vitro and in vivo by antibody directed against the ligand-binding domain of nuclear ER. The results suggest that estrogens may initiate membrane-associated signaling events leading to modulation of the growth and survival of breast cancers.
Results
Enrichment of high-affinity binding-sites with specificity for E 2 b in breast cancer cell plasma membranes
To con®rm earlier reports of membrane binding-sites for E 2 b Berthois et al., 1986; Pappas et al., 1995; Ramirez and Zheng, 1996; Levin, 1999; Watson and Gametchu, 1999) , we measured speci®c [ 3 H]E 2 b binding in subcellular fractions of MCF-7 cells after controlled cell homogenization and fractionation Szego, 1979, 1980) . With recovery of more than 97% of total E 2 b binding found in homogenates of MCF-7 cells, speci®c [ 3 H]E 2 b binding was distributed among crude nuclear, microsomal, mitochondria-lysosome and cytosol fractions ( Figure 1a ). After puri®cation of plasma membranes from the crude nuclear fraction by use of discontinuous-sucrose density gradient centrifugation, the PM fraction showed enhanced activity of 5'-nucleotidase, a plasma membrane marker enzyme, to about 23-times that of homogenate (Figure 1a ,b). Speci®c [ 3 H]E 2 b binding in plasma membranes was enriched to 28-times homogenate activity and represented 22% of homogenate binding. This data shows that speci®c E 2 b binding co-puri®es with a plasma membrane marker protein in membrane fractions from breast cancer cells. LDH activity, highly enriched in cytosol, is not signi®cantly detected in PM (Figure 1a,b) . In addition, cell DNA recovery was 94+3% of homogenate levels in nuclear fractions, and no DNA was detected in PM fractions (data not shown). Binding of [ Pietras and Szego, 1980) show that the dissociation constant for the binding process is 3.6610 710 M. Total binding sites in PM at saturation correspond to approximately 6.7 pmol E 2 b per mg membrane protein. In comparison with the estradiol binding properties of intact MCF-7 cells, plasma membrane estrogen-binding sites retain high anity for speci®c estradiol binding and exhibit signi®cant enrichment of ligand-binding capacity (see Figure 3) . Further, ligand speci®city of [ 3 H]E 2 b binding to PM was established by eective suppression by a 100-fold molar excess of unlabeled E 2 b (Figure 2b, inset) . In contrast, [ 3 H]E 2 b binding by PM was essentially unin¯uenced by these levels of estradiol-17a, progesterone or testosterone.
Identification of estrogen receptor forms in subcellular fractions after gel electrophoresis
To characterize putative estrogen receptor forms associated with PM fractions, samples were subjected to Western blot analysis, and blots were probed either with anti-ER antibody Ab2 or with E 2 b-POD (Luconi et al., 1999) . PM puri®ed from MCF-7 cells show signi®cant enrichment of a primary 67-kDa protein that reacts strongly with antibody Ab2 to LBD of nuclear ER-a (Figure 4a) . Similarly, breast cell nuclear fractions are enriched with this protein reactive with ER-a antibody (Figure 4a ). The 67-kDa band also shows evidence of speci®c labeling with E 2 b-POD (Figure 4b) . A secondary band at 46 kDa and minor bands at 62 kDa and 97 kDa were detected in PM and other cell fractions by use of Western blot ( Figure 4a ) and ligand-blotting (Figure 4b ). Using an antibody directed to ER-b, no signi®cant reactivity with proteins at the expected size of 58 ± 62 kDa was found in homogenate, nuclear or plasma membrane fractions of the MCF-7 cells (data not shown).
Rapid effects of E 2 b and E 2 b-BSA on activation of MAPK and Akt kinase in breast cancer cells Post-receptor signal transduction events, such as stimulation of MAPK, extracellular signal-regulated kinase ERK-1 (p44) and ERK-2 (p42) (Migliaccio et al., 1996; Levin, 1999) , may contribute to proliferative eects of E 2 b in breast cells. Thus, we assessed estrogen-induced phosphorylation of MAPK in MCF-7 cells in vitro. E 2 b, but not 17a-estradiol (E 2 a), promotes phosphorylation of MAPK isoforms, with eects evident within 2 min (Figure 5a ). To test whether activation of MAPK by E 2 b may be mediated by binding of estrogen to membrane-associated receptors, MCF-7 cells were treated with E 2 b linked to BSA, a macromolecular complex considered to be membrane-impermeant (Berthois et al., 1986; Ramirez and Zheng, 1996; Razandi et al., 1999; Russell et al., 2000) . Using E 2 b-BSA, but not control E 2 a-BSA, phosphorylation of MAPK isoforms is again evident within 2 min of steroid administration. Incubation of cells with antibody against LBD of ER (Ab2) inhibited MAP kinase phosphorylation induced by E 2 b or E 2 b-BSA. Similarly, we assessed signaling via the phosphatidylinositol-3 kinase (PI3K)/Akt pathway after treatment of MCF-7 cells with E 2 b or E 2 b-BSA. Both ligands induced signi®cant activation of Akt kinase (Figure 5b ), and inhibition of estrogen-induced eects occurred when cells were preincubated with ER antibody (Ab2), pure antiestrogen (ICI 182, 780) or the PI3K inhibitor, LY 294002.
To assess the potential for MCF-7 cell activation by free estradiol liberated from E 2 b-BSA, we transfected MCF-7 cells with an ERE-CAT reporter gene as before (Pietras et al., 1995) . Cells were exposed in vitro to free estradiol-17b or to E 2 b-BSA for only 10 min, then washed and incubated further. After 24 h, ERE-CAT reporter gene activity was measured. Short-term treatment with free estradiol-17b stimulated a marked increase in reporter gene activity (P50.001), but E 2 b-BSA elicited no signi®cant eect ( Figure 6 ).
Since interaction of E 2 b-BSA with plasma membrane binding-sites may be required for intracellular signaling (Berthois et al., 1986; Ramirez and Zheng, 1996; Razandi et al., 1999; Russell et al., 2000) , we evaluated binding of¯uorescein-labeled E 2 b-BSA (E 2 b-BSA-FITC) in MCF-7 cells. E 2 b-BSA-FITC binds at the surface of 77% of MCF-7 cells (Figure 7a (Figure 7e) , the E 2 b-BSA-FITC complex shows evidence of ligand speci®city, with signi®cant reduction (P50.01) of E 2 b-BSA-FITC binding by competition with equimolar amounts of free E 2 b, E 2 b-BSA, tamoxifen or ICI 182, 780, while the related steroid congener, progesterone, is not eective. Surface binding of E 2 b-BSA-FITC is also signi®cantly diminished by competition with antibody to the LBD of nuclear ER, suggesting some immunologic identity of the membrane site with nuclear ER (Figure 7c ,e). As expected, after permeabilization of cells by disruption of plasma membrane with detergent, intense labeling of ER in cell nuclei is found and occurs in 96% of breast cancer cells (Figure 7d ).
Inhibition of cell growth in vitro by antibody to ligand-binding domain of ER-a
Since antibodies to cell surface growth factor receptors are sometimes eective in blocking tumor cell growth (Pietras et al., 1994) , the antiproliferative activity of antibodies to ER-a was evaluated using MCF-7 cells in vitro. The estrogen-dependent MCF-7 cells show enhanced proliferation after treatment with E 2 b, but not E 2 a (Figure 8a ). However, prior exposure to LBD Ab1 or LBD Ab2 elicits a signi®cant reduction (P50.05) in the growth response to E 2 b (Figure 8a ).
Since some recent studies suggest that the proliferative response to E 2 b is committed within 1 min and is evoked by activation of only a small fraction (45%) of ER (Chun et al., 1998) , we assessed the growth of breast cells after brief treatment with E 2 b-BSA. MCF-7 Figure 1 Distribution and relative speci®c activities of enzymes and speci®c [ 3 H]estradiol-17b binding in plasma membrane and other subfractions of MCF-7 breast cancer cells. Cells were grown in estrogen-free media prior to harvesting, then disrupted using controlled homogenization methods as before Szego, 1979, 1980) . ( 
Inhibition of breast tumorigenesis in vivo by antibody to ligand-binding domain of ER-a
The antitumor activity of antibodies to ER-a was evaluated further using MCF-7 tumors in vivo. MCF-7 cells were grown as subcutaneous xenografts in female athymic mice primed with E 2 b to promote growth of these estrogen-dependent cells (Pietras et al., 1995) . Antibody or control treatments were initiated when tumors grew to 430 mm 3 . Anti-ER Ab2 was administered in six doses over a 26-day period. The results show that antibody to ER, but not control immunoglobulin, elicits a signi®cant suppression of tumorigenesis of human MCF-7 breast cancer xenografts in female nude mice treated concomitantly with E 2 b (Figure 8b ).
Discussion
It is generally held that the biologic activity of estrogen in the breast is mediated through receptors that act in breast cell nuclei (Evans, 1988) . However, E 2 b is also well known to elicit rapid membrane-initiated signaling with an onset in seconds to minutes (Zyzek et al., 1981) , and these eects are poorly explained by a pure genomic model of hormone action (Szego and Pietras, ]estradiol-17b by MCF-7 cells was determined by methods described elsewhere (Pietras and Szego, 1979; Pietras et al., 1995) . A 100-fold molar excess of unlabeled estradiol-17b was present with [ 1984; Ramirez and Zheng, 1996; Levin, 1999; Watson and Gametchu, 1999) . Many studies have provided evidence for a membrane-associated form of ER Nemere and Farach-Carson, 1998; Levin, 1999; Watson and Gametchu, 1999) . The present work extends these observations in studies with breast cancer cells and suggests that targeting of membrane-associated forms of ER may elicit a potent antitumor eect.
As with anity-binding strategies used to identify peptide hormone receptors at the cell surface, estrogenbinding sites were identi®ed at the surface of breast cancer cells by exposure to estradiol conjugated with uorescein-BSA (Nenci et al., 1981; Berthois et al., 1986; Ramirez and Zheng, 1996) or with biotin (Germain et al., 1993) . Macromolecule-bound forms of E 2 b, such as E 2 b-BSA, are generally considered membrane-impermeant and are more water-soluble than free E 2 b (Ramirez and Zheng, 1996; Razandi et al., 1999; Russell et al., 2000) . These conjugates were ®rst used as immunogens and for anity puri®cation of nuclear forms of ER (Sica et al., 1973) . However, on extended incubation, E 2 b-BSA is not stable in solution, especially in the presence of cells, and may release measurable amounts of free steroid (Stevis et al., 1999) . To promote the absence of free E 2 b in these experiments, aliquots of E 2 b-BSA were preabsorbed with DCC under conditions that remove 499% of free hormone , and experiments were conducted with only brief exposure of intact cells to E 2 b-BSA. In addition, in order to assess the potential for cell activation by free estradiol liberated from E 2 b-BSA in our studies, we transfected MCF-7 cells with an ERE-CAT reporter gene and found that E 2 b-BSA elicited no signi®cant increase in reporter gene activity. This indicates that, under the conditions of our experiments, neither E 2 b-BSA nor dissociated estradiol enters the cell to bind and stimulate the ERE, a ®nding consistent with prior reports (Watters et al., 1997; Razandi et al., 1999 Razandi et al., , 2000 Russell et al., 2000) . Further, binding of E 2 b-BSA to the surface of MCF-7 cells was speci®c, with little competition by E 2 a-BSA or progesterone. About 77% of MCF-7 cells had plasma membrane binding-sites for speci®c interaction with E 2 b-BSA, but the relative concentration of estradiol binding-sites in membrane is substantially less than that found in cell nuclei after cell permeabilization. In additional control studies, cells with no expression of ER-a did not exhibit surface labeling with E 2 b-BSA, thus con®rming previous reports by Berthois et al. (1986) .
Despite renewed interest in membrane-associated forms of ER, the identity of these receptors still remains elusive. These receptors may be known membrane molecules with previously unknown binding sites for E 2 b, new forms of ER, classical ER complexed with other membrane-associated proteins or truly novel membrane proteins Nemere and Farach-Carson, 1998; Levin, 1999; Watson and Gametchu, 1999) . Early work on puri®cation of estrogen-binding components from uterus and liver plasma membranes suggested that it was a protein species with high-anity binding for E 2 b and with a molecular size in the range of nuclear ER Szego, 1979, 1980) . To determine whether the membrane-associated receptor had antigenic homology with nuclear ER, Pappas et al. (1995) used antibodies prepared to dierent functional epitopes of nuclear ER and demonstrated signi®cant surface labeling in intact pituitary cells by confocal scanning laser-microscopy. Using human endothelial cells, Russell et al. (2000) independently con®rmed that surface binding-sites for estradiol react speci®cally with antibodies directed to ER-a. To evaluate the source and distribution of membraneassociated ER, Razandi et al. (1999) transfected cDNA for ER-a and ER-b into CHO cells that do not normally express these genes. Expression of a single cDNA encoding either receptor gave rise both to nuclear and membrane ER, suggesting that membrane and nuclear ER derive from a single transcript. The anity of the receptors for E 2 b in both sites was nearly identical, but a greater number of receptors was detected in cell nuclei. In addition, both ER-a and ER-b membrane receptors could Using a ligand-blot approach, binding of E 2 b-POD to a 67-kDa band is likewise found to be enriched in plasma membranes (PM) and in nuclear (N) fractions. E 2 b-POD binding is shown in the absence (none) and presence (E 2 b) of free estradiol-17b at a 10-fold molar excess in order to assess speci®c steroid binding (Luconi et al., 1999) signal to MAPK which was necessary for activating DNA synthesis (Razandi et al., 1999) .
In attempting to isolate and purify membraneassociated estrogen-binding proteins from breast cancer cells, this study has begun to further elucidate molecular properties of the membrane-associated receptor in malignant cells. After use of controlled and quantitative cell fractionation procedures to preserve the integrity of subcellular structures Szego, 1979, 1980) , the bulk of speci®c E 2 b binding in MCF-7 cells is found in nuclear fractions. However, a signi®cant portion of speci®c E 2 b-binding sites also occur in association with plasma membranes. These E 2 b binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and appear to be free from signi®cant contamination by cytosol or nuclei. The plasma membrane E 2 b binding-sites constitute about 20% of total cell binding-sites for the steroid, a level of membrane concentration comparable to that found for other known transmembrane hormone receptors (Bergeron et al., 1986) . In addition, monoclonal antibodies against the LBD of nuclear ER can identify membrane-associated ER in MCF-7 cells, a ®nding consistent with studies with other cell types (Pappas et al., 1995; Razandi et al., 1999; Russell et al., 2000) . The primary membrane-associated protein reactive with antibodies to LBD of nuclear ER-a and with E 2 b ligand is 67-kDa, a molecular size comparable to that of nuclear ER-a, but additional protein species, notably at 46-kDa, were also detected (Green et al., 1986; Monje and Boland, 1999) . Two forms of ER-a with molecular masses of 67 kDa and about 46 kDa occur in target cells, including vascular endothelial cells and MCF-7 cells (Flouriot et al., 2000) , and in HeLa cells transfected with ER cDNA (Green et al., 1986) . The occurrence of the truncated receptor form may be due, in part, to limited protein degradation or to alternative translation (Flouriot et al., 2000) . The smaller receptor form does not appear to be related to ER-b. Antibody directed to ER-b did not react with proteins at the expected size of 58 ± 62 kDa in homogenate, nuclear or plasma membrane fractions of MCF-7 cells (see Fuqua et al., 1999) . This is consistent with several reports that ®nd little to no ER-b transcripts in MCF-7 cells (Register and Adams, 1998; An et al., 2001) . Finally, a minor band at 97-kDa was detected in plasma membrane and other cell fractions by use of immunoblotting with antibodies to ER-a and with ligand-blotting. This large species may be related to a membrane steroid receptor of high molecular size as reported by others (Chen et al., 1999; Watson and Gametchu, 1999 ). These data suggest that membrane-associated estrogen-binding proteins contain common structural elements, at least in key molecular domains, with ER-a and various splice variants. The classical receptors contain several hydrophobic regions, but it is not known if these are sucient to allow disposition as an integral membrane protein (Green et al., 1986) . However, a distinct E 2 b-binding protein that diers from nuclear ER may also occur (cf. Hawkins et al., 2000) . Using ER-gene knockout mice, Gu et al. (1999) ®nd that some rapid actions of estradiol on kainateinduced currents in neurons still occur and are not inhibited by ICI 182, 780, a pure antagonist of hormone binding to both ER-a and ER-b. However, one diculty with interpretation of these ®ndings is that uterine tissues from ER-gene knockout mice exhibit up to 10% of estradiol binding present in wild-type uteri (Couse et al., 1995) , and the nature of these residual estrogen-binding sites in ER-knockout target cells remains unde®ned (Flouriot et al., 2000) . It is notable that Welshons et al. (1993) enucleated MCF-7 cells and found that the resulting cytoplast fractions contained about 15% of total cellular ER content, possibly attributable to plasma membrane-associated receptor forms. ER in membranes may also be contained in multimeric complexes with other transmembrane molecules coupled to speci®c signaling cascades (Mendelsohn and Karas, 1999; Simoncini et al., 2000) . This proposal is supported by reports of estrogen receptor forms in 100-nm vesicular invaginations of plasma membrane and in association with caveolin and other components of caveolae (Kim et al., 1999; Chambliss et al., 2000) , a plasmalemmal microdomain involved in the assembly of signaling complexes. It is clear that further puri®cation of the estradiol-binding component associated with surface membrane will be required to assess the true composition of this molecule.
The estrogen receptor plays a central role in regulating cell proliferation in human breast epithelium (Henderson et al., 1988) . Estrogen action leading to growth includes activation of early response genes, cell cycle-regulatory gene products and growth factors (Evans, 1988; Henderson et al., 1988; Murdoch and Gorski, 1991; Weisz and Bresciani, 1993) . However, the initial targets of estrogens leading to regulation of Figure 6 Activation of an ERE-CAT reporter gene by free estradiol-17b but not by E 2 b-BSA. Using established procedures (Pietras et al., 1995) , MCF-7 cells were transfected with a reporter plasmid containing a palindromic estrogen responsive element (ERE) and the chloramphenicol acetyltransferase (CAT) gene, termed ERE-CAT. Transfected cells were treated with free estradiol (1 nM) or with DCC-treated E 2 b-BSA (500 nM) for 10 min, washed extensively and incubated further to 24 h. Thereafter, CAT protein was quantitated in cell extracts and normalized for total protein content in each sample in three independent experiments. In additional control experiments, neither free estradiol nor E 2 b-BSA elicited stimulation of a control ERE reporter gene construct transfected in MCF-7 cells as before (Pietras et al., 1995) the expression of these molecules remain to be identi®ed. As noted above, studies on a variety of target cells suggest that estradiol elicits rapid downstream eects to activate membrane G proteins, inositol phosphate production, adenylate cyclase, calcium, and receptor tyrosine-kinases (Migliaccio et al., 1996; Levin, 1999; Watson and Gametchu, 1999) . Estradiol stimulation of breast, bone and vascular endothelial cells is associated with rapid activation of MAPK activity that appears to be independent of transcription (Improta-Brears et al., 1999; Razandi et al., 1999; Russell et al., 2000) . These signaling cascades are postulated to promote the later activation of transcription, DNA synthesis and growth (Razandi et al., 1999) .
Our studies provide additional con®rmation of membrane-initiated signal transduction by ER in breast cancer cells, including interactions with signaling pathways such as MAPK and Akt kinase. Independent reports showing a lack of MAPK activation in the absence of ER (Improta-Brears et al., 1999; Razandi et al., 1999) and the ability of pure antiestrogen, ICI 182, 780, to inhibit estrogen-induced MAPK activity in MCF-7 cells (Improta-Brears et al., 1999) strongly implicate ER in this pathway and de®ne a potentially important link between estradiol and the cell cycle. In the present work, estradiol-17b promotes the phosphorylation of MAP kinase isoforms within 2 min, and these rapid stimulatory eects of free E 2 b appear to be equaled by E 2 b-BSA in vitro. In contrast, steroidal ligands that do not promote cell growth, the biologically-inactive estradiol-17a and E 2 a-BSA, do not elicit acute changes in MAP kinase activity. Moreover, the eect of estradiol-17b is abolished by prior incubation of cells with antibody to ER-a or by selective inhibition of the MAP kinase signaling pathway. The ability of a macromolecular antibody to ER to rapidly inhibit estrogen-induced MAP kinase phosphorylation strongly implicates ER in this pathway and suggests an important link between a membrane-associated receptor and cell cycle regulation. In addition, the serine/threonine kinase Akt, a downstream eector of PI3-kinase, has been implicated in cell survival and prevention of apoptosis in MCF-7 cells (Ahmad et al., 1999) . Estradiol-17b acutely activates Akt kinase, and the hormone-induced eects Figure 8 Inhibition of MCF-7 breast cancer cell growth by a monoclonal antibody directed against the LBD of nuclear ER. (a) Cells were incubated in vitro for 2 h with anti-ER antibodies directed against the LBD (Ab1 and Ab2) or with a control antibody directed to the D and E-domains of ER (Ab3). Thereafter, E 2 b, 17a-estradiol (E 2 a), E 2 b-BSA or E2a-BSA were added to cultures for 10 min. Cells were then cultivated further, and ®nal cell numbers were quantitated after 72 h for each treatment group as indicated. Data (mean+s.e.m.) were collected from at least four independent experiments. (b) Monoclonal antibody directed against the LBD of ER-a reduces growth of human MCF-7 breast tumor cell xenografts in vivo. Female nude mice were primed by treatment with E 2 b subcutaneously, then inoculated with MCF-7 cells as before (Pietras et al., 1995) . After 10 ± 14 days, animals with tumors of comparable size were randomized to treatment groups of 6 ± 8 mice. Treatments included IgG isotype-control antibody (CON) or monoclonal antibody directed against the LBD of ER-a (Ab2) administered intraperitoneally twice weekly for a total of 6 doses. After 26 days, no further antibody treatment was given. Tumor volumes were recorded by micrometer measurements, with results shown as mean+s.e.m.
are inhibited by preincubation of cells with ER antibody, ICI 182, 780 or a speci®c PI3 kinase inhibitor. Again, the ability of antibody to ER and of a pure antiestrogen to inhibit early estrogen-induced Akt kinase activity implicates ER in this pathway and suggest an important association between a membraneassociated receptor and the regulation of a cell survival signaling pathway. Both promotion of cell proliferation and blockade of cell death by membrane-associated estrogen receptors may contribute to the aberrant phenotype of breast cancer cells (see Razandi et al., 2000) .
Our studies suggest that activation of membraneassociated forms of ER contribute to promotion of tumorigenesis of breast cancers. Treatment of breast cancers with macromolecular antibodies directed to the LBD of nuclear ER block the growth of tumors that bear functional ER. This ®nding parallels the report by Nor¯eet et al. (2000) showing that antibodies to ER can modulate rapid prolactin release from pituitary tumor cells with membrane-associated ER. Further study will be required to assess the ecacy of ER antibodies in larger established tumors. Nevertheless, these ®ndings oer support for earlier reports showing that estrogen-induced membrane signaling leads to the later activation of DNA synthesis and cell growth (Razandi et al., 1999) . It is likely that primary E 2 b-induced activation of membrane-associated ER will also aect subsequent hormonal interactions with nuclear ER to promote activation of transcription and cell proliferation. Similarly, the molecular details of cross-communication between estrogen and peptide receptors are beginning to emerge Kato et al., 1995; Pietras et al., 1995) , and membrane ER may be in a pivotal cellular location to enhance convergence among diverse signaling pathways. Since more than 60% of human breast cancers express ER at diagnosis (Henderson et al., 1988) , biologically-based therapies in the form of antiestrogens have been a mainstay in breast cancer treatment. A novel approach to antitumor therapy with blood-borne anti-receptor agents could represent an important addition to available treatment options. In promoting a hypothesis of estrogen action via both nuclear and membraneassociated receptors, this work may lead to development of previously unsuspected antitumor therapies targeted to breast cancers.
Materials and methods
Cell culture and assay of cell proliferation in vitro MCF-7 human breast cancer cells (ATCC) were maintained in RPMI 1640 medium with 10% fetal bovine serum (FBS). For estrogen-free conditions, medium was changed 48 h before experiments to phenol-red free RPMI 1640 with 1% dextran-coated, charcoal-treated (DCC) FBS (Pietras et al., 1995) . In experiments using 17b-estradiol 17-hemisuccinate covalently linked to bovine serum albumin (E 2 b-BSA, Steraloids, Newport, RI, USA), aliquots of E 2 b-BSA were preabsorbed with DCC to remove free steroid by established methods .
To assess eects of ER antibodies on cell proliferation in selected experiments, cells were ®rst incubated with antibodies directed against dierent domains of ER-a: Ab1, against a segment of the ligand-binding domain (LBD) from amino acids 495 ± 595 (Upstate Biotechnology, Lake Placid, NY, USA); Ab2, against a longer segment of the LBD, from amino acids 302 ± 595 (Neomarkers, Fremont, CA, USA) and Ab3 against segments of the hinge-region, HSP 90-and DNA-binding domains, from amino acids 280 ± 335 (NeoMarkers). Incubation with antibodies for 2 h was followed by addition of either 10 nM E 2 b, 100 nM E 2 a (17a-estradiol, Steraloids), 0.5 mM E 2 a-BSA (6 keto-17a-estradiol 6-(ocarboximethyloxime:BSA, Steraloids) or 0.5 mM E 2 b-BSA for 10 min. After 72 h, cells were counted to estimate rates of cell proliferation, using data from four independent experiments.
Specific binding of estradiol-17b in breast cancer cells
Speci®c E 2 b binding was assessed in MCF-7 cells using [2, 4, 6, 7, 16, H]estradiol-17b (NEN, Boston, MA, USA) as reported previously Szego, 1979, 1980; Pietras et al., 1995) . A 100-fold molar excess of unlabeled estradiol-17b was present with [ 3 H]estradiol-17b in paired samples for determination of displaceable binding.
Cell homogenization and subcellular fractionation
Cell fractionation was done as before with methods designed to preserve the integrity of subcellular structures Szego, 1979, 1980; Pietras et al., 1995) . In brief, cells were harvested with ice-cold Versene in the presence of protease inhibitors, then homogenized using a Dounce homogenizer. Whole homogenate (H) was ®ltered through nylon mesh and centrifuged at 1000 g for 10 min to yield crude nuclear (N) and post-nuclear supernate fractions. The N fraction was resuspended in 31% sucrose in buer, loaded on top of a discontinuous sucrose density-gradient and centrifuged at 67 000 g for 2 h. Plasma membranes occurred predominantly at r=1.13 ± 1.16 (PM) (Pietras and Szego, 1979) . The postnuclear supernatant was centrifuged at 15 000 g for 30 min, with the resulting pellet representing the mitochondria-lysosome fraction (ML). The supernate was centrifuged at 105 000 g for 1 h to yield the microsomal pellet fraction (Ms) and the soluble cytosol fraction (S). Extracts from cell membranes were solubilized as before (Monje and Boland, 1999) . Protein was quantitated using the BCA-200 Protein Assay Kit (Pierce, Rockford, IL, USA).
Analyses of enzyme activity, DNA, estrogen receptor and [
H]estradiol-17b binding assay in subcellular fractions
Activity of 5'-nucleotidase (EC 3.1.3.5) was determined by established methods, with speci®c activities given as nmol/ min/mg Szego, 1979, 1980) . Activity of lactate dehydrogenase (LDH) was assessed as before (Weiler and Wiebe, 2000) . Relative speci®c activity represents the speci®c activity of enzyme in a given fraction in relation to that in homogenate. DNA was determined by established methods (Pietras and Szego, 1980) . Speci®c E 2 b binding was assessed in cell fractions using [2, 4, 6, 7, 16, H] estradiol-17b (NEN) as reported previously Szego, 1979, 1980) . To characterize putative estrogen receptor forms associated with PM fractions, membrane proteins were separated by SDS ± PAGE and then transferred to a nitrocellulose membrane for immunodetection by Western blot. The blots were probed as before (Pietras et al., 1995) with ER-a antibodies, Ab1 (Upstate Biotechnology) or Ab2 (Neomarkers), ER-b antibody (PA1-310B; Anity Bioreagents, Golden, CO, USA) or E 2 b-POD (Luconi et al., 1999) .
Determination of p44/42 MAPK and Akt kinase activity Cells were maintained in estrogen-free conditions 48 h before the experiment. In selected studies, cells were pre-incubated 90 min with U0126 (25 mM), a selective inhibitor of MEK1 and MEK2 (Favata et al., 1998) or for 2 h with anti-LBD Ab-2 (10 mg/ml) before treatment with estrogens. Protein samples were separated by SDS ± PAGE and then transferred to a nitrocellulose membrane for immunodetection with antiphospho-p44/p42 MAP kinase (Thr202/Tyr204) polyclonal antibody (New England Biolabs, Beverly, MA, USA), using the Pierce Western blotting system. Akt activity was measured by Western blot using the Akt kinase assay kit (Cell Signaling Technology, Beverly, MA, USA). After growth in estrogen-free conditions, cells were pre-incubated with anti-LBD Ab-2 (10 mg/ml), anti-PI(3) kinase inhibitor LY294002 (10 mM) or ICI 182,780 (1 mM) (Astra Zeneca, Newark, DL, USA), followed by treatment with 10 nM E 2 b or 0.5 mM E 2 b-BSA for 20 min. Lysates were incubated overnight with anti-Akt kinase antibody. Thereafter, immunoprecipitates were processed for assay of Akt kinase activity according to recommendations of the manufacturer. Akt activity was assessed by densitometric analysis of phosphorylated GSK-3 using the public domain NIH Image program.
Transfection of cells with ERE-CAT reporter gene constructs
A reporter plasmid containing a palindromic estrogen responsive element (ERE) and the chloramphenicol acetyltransferase (CAT) gene was used in these studies and is termed ERE-CAT (Pietras et al., 1995) . MCF-7 cells were prepared and transfected using established procedures (Pietras et al., 1995) . CAT protein was quantitated in cell extracts using a non-radioactive enzyme-linked immunosorbant assay (5 Prime-3 Prime, Boulder, CO, USA), with about 50 pg of CAT protein per ml of cell extract found to be the lower limit of detection. CAT reporter activity was normalized for the protein content in each sample.
Membrane labeling with estradiol and flow cytometry
Single cell suspensions of MCF-7 cells from estrogen-free cultures were obtained using Versene (GIBCO BRL, Rockville, MD, USA). Cells were incubated at 48C for 15 min with 1 mM¯uorescein isothiocyanate (FITC)-labeled BSA with covalently-attached 17b-estradiol-hemisuccinate (E 2 b-BSA-FITC) (Berthois et al., 1986) . In selected control experiments, ER-positive ZR75-1 human breast cancer cells (ATCC) or ER-negative MDA-MB-231 human breast cancer cells (ATCC; Berthois et al., 1986) or COS-7 monkey kidney cells (ATCC) were labeled under similar conditions. For competition studies, MCF-7 cells were incubated 5 min with 100 nM E 2 b, 1 mM E 2 b-BSA, 1 mM ICI 182,780, 100 nM progesterone or 10 mg/ml ER antibody Ab1. A sample was analysed by microscopy, and the remainder was used for¯ow cytometry using a FACScan with Cell Quest software (Beckton Dickinson, Franklin Lakes, NJ, USA). To facilitate nuclear staining, some cells were permeabilized with 0.1% Triton X-100 (Razandi et al., 1999) .
Human tumor xenografts in nude mice
MCF-7 cells were inoculated subcutaneously at 5610 7 cells/ animal in the mid-back region of 3-month-old female athymic mice (Charles River, Wilmington, MA, USA) primed with E 2 b in a biodegradable binder as before (Pietras et al., 1995) . Treatment was initiated when tumors grew to 430 mm 3 . Animals were randomized by weight and tumor size at the start of the experiment, with 6 ± 8 animals included in each treatment group. Antibody and control solutions were administered by intraperitoneal injection. Anti-ER LBD Ab2 was given at a dose of 3.5 mg/kg in 6 doses at 4-day intervals (over 26 days). Control injections with mouse IgG 1 (Pharmingen, San Diego, CA, USA) were given on an identical treatment protocol.
